Indegene Ltd Q3 FY2025 Concall Summary

Key Takeaways

• Steady quarter, cautious macro: Revenue grew 4.9% QoQ with 240 bps EBITDA margin expansion, while management flagged calendar year 2025 as a year of cautious recovery for the industry.
• Mid-tier pharma driving growth: Seven new clients added, all beyond the top 20 global pharma, and the 20-100 cohort is showing faster decision cycles and first-time outsourcing opportunities.
• Internal GenAI bet overrides acquisition: Management wrote off its €1.5M TriloDocs investment because an internal GenAI initiative is yielding better results, signaling a build-over-buy pivot in technology development.
• Productivity gains absorbing wage costs: Automation and capacity management offset the wage bill hike, but some benefits will be passed to customers to remain competitive.
• What to watch next quarter: Whether large-scale expansion pursuits with top 10-20 customers close after slower-than-expected progress, and how the Spain and Hyderabad hiring translates into revenue.

Revenue Growth & Client Dynamics

• Enterprise segment steady: Enterprise Commercial and Medical Solutions grew 3.7% sequentially, driven by mid-sized pharma clients beyond the top 20 globally ranked players.
• Omnichannel lumpy by nature: Grew 11.8% QoQ due to project revenue and non-enterprise work kicking off, but carries finite-life projects (6 months) that explain YoY declines despite sequential strength.
• Top 5 accounts stabilizing: Largest customer run rate just below USD5 crore; two previously flagged accounts showing stabilization of business and revenues.
• Client pyramid upgrading: Active clients moving from sub-USD1M to USD1M+ and from 1-5 crore to 5-10 crore ranges, with existing 5-10 crore customers growing within that band.
• New account ambition: New accounts beyond the top 20 have potential to become \$25-\$35 million and even \$50 million accounts over time.
• Geographic mix shift: North America 69.3%, Europe 27.9%, a shift of just under 1% from North America to Europe.

Manish Gupta: "However, given that these are large companies and what we do for them is not standard business as usual but a shift in their operating models, the cycle times might vary. Hence, we are calling out this mid to long term."

Margins & Productivity

• EBITDA margin jump: Improved 240 bps QoQ to 20.8% as productivity initiatives through better capacity management and automation absorbed the wage bill hike impact that had hit the previous quarter.
• Headcount reduction deliberate: Employee count fell due to productivity initiatives, automation (GenAI, RPA), and output-based pricing contracts; revenue per employee is increasing.
• Delivery mix shifting: Automation reduces need for certain skill sets (e.g., HTML coding), while domain-specific automation (medical writing, regulatory dossier processing) takes longer due to technology maturity; domain experts are retained to operate automated systems.
• Subcontracting cost spike temporary: Driven by Spain office registration where people were onboarded through third-party providers ahead of formal registration; costs will regularize as people move to payroll.
• Offshore mix declined: Trilogy acquisition was entirely onsite, and new engagements start onsite-heavy due to change management needs; offshore scales up as engagements stabilize.

Suhas Prabhu: "In the longer run would also have to pass on some of these benefits to the customers to remain ahead of the curve in the market and be competitive."

AI, Automation & Build-vs-Buy

• TriloDocs written off: Full write-off of €1.5M convertible loan after nine months of insufficient revenue progress and technology not yet market-ready; management chose to double down on internal GenAI initiatives that are yielding better results.
• Domain expertise as AI moat: Management believes domain expert companies will drive the AI automation agenda, as non-domain tasks get automated while domain specialists operate the systems.
• Productivity pass-through: Automation benefits contribute positively to margins and help offset wage impacts, but some benefits will be passed to customers to remain competitive, making this a continual rather than one-time margin lever.

Manish Gupta: "We are very clear that we were having internal initiative. We saw this thing being developed, we did a holistic deal with Trilogy and TriloDocs and we thought about the whole deal in totality. Now what we saw is our internal effort on technology which is much more GenAI based is yielding better results and we are convinced about that direction more than what TriloDocs was doing and that we wanted to have as an option value."

Competitive Landscape & Market Structure

• Veeva-Salesforce tug-of-war a net positive: Management sees the platform competition as potentially beneficial for Indegene, as migration and transformation work increases regardless of which platform wins.
• Top 20 pharma expansion: Subscale customers engaged with first operating models; large customers discussing centralizing higher-value steps (3-5) currently done by agencies, representing market share gain opportunity in commercial segment.
• 20-100 cohort dynamics: Combination of first-time outsourcing (work previously done internally) and market share gains from other players; solutions created specifically for mid-tier companies with shorter decision cycles.
• Drug pricing pressure: Downward pressure on drug prices will stress biopharma business models and margins, creating both headwinds and outsourcing opportunities.

Manish Gupta: "We agree with that thing there is a tug of war between Veeva and Salesforce and from our perspective, actually there could be a net positive, right given this development for us."

M&A & Capital Allocation

• Acquisition pipeline active: Scouting for sub-\$50-\$60 million revenue companies, ranging from \$2 to \$50 million, focused on omnichannel capabilities, geographical expansion, business technology (Veeva/Salesforce migration), analytics, and regulatory/medical side.
• Size not primary criteria: Acquiring credibility and capability in adjacent, upstream, or downstream areas; could be very small acqui-hire type deals.
• CultHealth earnout fully settled: Final settlement resulted in write-back of ₹15.7 crore in other income as payout was lower than liability carried in books; no deferred liability remains from any past acquisition.

People & Geographic Expansion

• Spain entry: Registered presence in Spain and started recruiting locally; subcontracting costs elevated temporarily as people were onboarded through third-party providers ahead of registration.
• London expansion: Moved to 1,800-person capacity office in November.
• Hyderabad hiring: Added approximately 200 people in Hyderabad and vicinity in November.
• Automation reshaping roles: Domain-specific automation (medical writing, regulatory dossiers, safety case processing) takes longer to mature; domain experts retained to operate automated systems rather than being displaced.

Manish Gupta: "We believe more and more as you see AI automation happening, the domain expert companies, us and any other people in other domains will be the guys who will drive that agenda."

Guidance & Commitments

Key Metrics